Study of SGR-1505 in Mature B-Cell Neoplasms

ClinicalTrials.gov ID: NCT05544019

Public ClinicalTrials.gov record NCT05544019. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Sep 3, 2026, 3:06 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 1, Open-Label, Multicenter, Dose Escalation Study of SGR-1505 as Monotherapy in Subjects With Mature B-Cell Malignancies

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The purpose of this study is to evaluate safety and tolerability and to determine the maximum tolerated dose (MTD) or maximum administered dose (MAD) and/or recommended dose (RD) of SGR-1505.

Study identification

NCT ID: NCT05544019
Recruitment status: Recruiting
Study type: Interventional
Phase: Phase 1
Lead sponsor: Schrödinger, Inc.; Industry
Enrollment: 98 participants

Conditions and interventions

Conditions

Interventions

SGR-1505 Drug

Drug

Eligibility (public fields only)

Age range: 18 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Apr 9, 2023
Primary completion: Oct 31, 2027
Completion: Oct 31, 2027
Last update posted: Feb 12, 2026

2023 – 2027

United States locations

U.S. sites: 16
U.S. states: 13
U.S. cities: 16

Facility	City	State	ZIP	Site status
Banner Health - MD Anderson Cancer Center	Gilbert	Arizona	85234	Recruiting
Christiana Care Hospital - Helen F Graham Cancer Center	Newark	Delaware	19713	Recruiting
Napa Research	Pompano Beach	Florida	99064	Recruiting
Beth Israel Deaconess Medical Center	Boston	Massachusetts	02215	Recruiting
Regional Cancer Care Associates	Hackensack	New Jersey	07601	Recruiting
Roswell Park Comprehensive Cancer Center	Buffalo	New York	14203	Recruiting
Weill Cornell	New York	New York	10065	Recruiting
Montefiore Medical Center	The Bronx	New York	10467	Recruiting
Duke University	Durham	North Carolina	27710	Recruiting
Gabrail Cancer & Research Center	Canton	Ohio	44718	Recruiting
The Ohio State University - The James Cancer Hospital	Columbus	Ohio	43210	Recruiting
Oregon Health and Science University - Knight Cancer Institute	Portland	Oregon	97329	Recruiting
Rhode Island Hospital	Providence	Rhode Island	02903	Recruiting
University of Texas Southwestern	Dallas	Texas	75390	Recruiting
Fred Hutchinson Cancer Center	Seattle	Washington	98109	Recruiting
Medical College of Wisconsin	Milwaukee	Wisconsin	53226	Recruiting

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 20 non-U.S. sites.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT05544019, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Feb 12, 2026 · Synced Sep 3, 2026

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT05544019 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →